Drugs / RSV F subunit
RSV F subunit
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02298179 | Dec 2014 → Mar 2017 | respiratory syncytial virus infectious disease | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RSV F subunit | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02298179 ↗ |
| Known as | RSV F subunit vaccine | “An investigational vaccine using an engineered recombinant RSV fusion glycoprotein in its post-fusion conformation (RSV F subunit vaccine) has been developed” PMID 30987852 ↗ Apr 2019 |
| Known as | RSV subunit F vaccine | “CONCLUSIONS: A single dose of each formulation of RSV subunit F vaccine was well-tolerated and enhanced preexisting NAb titers through six months of follow-up.” PMID 30987852 ↗ Apr 2019 |
| Modality | Vaccine | “An investigational vaccine using an engineered recombinant RSV fusion glycoprotein in its post-fusion conformation (RSV F subunit vaccine) has been developed” PMID 30987852 ↗ Apr 2019 |